We offer daily assistance for technical and scientific matters.
Multiple Myeloma
Worldwide key player in diagnosis and monitoring of Multiple Myeloma patients.
Multiple Myeloma, also known as Kahler’s disease, is the second most common blood cancer worldwide, with nearly 188,000 new cases diagnosed each year.
Multiple Myeloma is typically diagnosed in older individuals between 65 and 74 years old, but people younger than 50 can also exhibit symptoms.
Over the past two decades, the incidence of multiple myeloma has steadily increased, mainly due to the aging of the global population and improvements in diagnostic practices.To date, the risk factors that trigger the transformation and uncontrolled multiplication of plasma cells are not well known.
What is Multiple Myeloma?
Multiple Myeloma is a cancer characterized by the proliferation of a clone of plasma cells in the bone marrow and induces overproduction of immunoglobulins (antibody proteins) that crowd out the normal blood-forming cells and prevent them from functioning effectively.
The symptoms of Multiple Myeloma include bone lesions, anaemia, kidney damage and susceptibility to infections. Patients commonly experience bone pain and fractures, also experiencing weight loss, tiredness and repeated infections.
The tumour plasma cell clone proliferation induces high levels concentration of Monoclonal protein (also called M-Protein) which is the best tumour markers of the disease.
Early detection and accurate monitoring are key to improving outcomes and guiding effective management of Multiple Myeloma.
2nd
most common Blood Cancer
188k
new cases each year
40%
of multiple myeloma patients experience symptoms for more than six months before the disease is diagnosed
Knowledge & Science
We aim to educate and share scientific and medical educational information with our customers all around the world.
Understand in 2 minutes how capillary electrophoresis works, and why it gives such high and clear resolution in lab testing.
Instruments for diagnosing Multiple Myeloma
The compact and affordable automation of Capillary Electrophoresis.
Evolution makes the difference.
A concentrate of Sebia’s expertise in a high throughput instrument.
Capillary Electrophoresis solution to meet your high capacity needs.
The high throughput solution for newborn hemoglobin disorders screening.
Large menu with high quality results on gel electrophoresis.
Efficiency re-dIFined.
Authentically clear!
Small Footprint - Big Impact.
This section contains information intended for wide distribution and may therefore contain product details or information that is not available or valid in your country. Please contact your local Sebia representative. Information intended for healthcare professionals. Carefully read the instructions in the reagent package inserts and instrument manuals.